H
0.823
0.03 (3.60%)
| Previous Close | 0.794 |
| Open | 0.821 |
| Volume | 7,485,481 |
| Avg. Volume (3M) | 6,413,333 |
| Market Cap | 179,411,136 |
| Price / Earnings (Forward) | 23.81 |
| Price / Sales | 71.34 |
| Price / Book | 57.77 |
| 52 Weeks Range | |
| Earnings Date | 27 Mar 2026 |
| Operating Margin (TTM) | -4,484.33% |
| Diluted EPS (TTM) | -0.690 |
| Total Debt/Equity (MRQ) | 228.93% |
| Current Ratio (MRQ) | 3.68 |
| Operating Cash Flow (TTM) | -99.38 M |
| Levered Free Cash Flow (TTM) | -67.40 M |
| Return on Assets (TTM) | -42.82% |
| Return on Equity (TTM) | -249.75% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Humacyte, Inc. | Bearish | Bearish |
AIStockmoo Score
-0.1
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | -2.5 |
| Average | -0.13 |
|
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 20.16% |
| % Held by Institutions | 40.20% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 25.00 (D. Boral Capital, 2,937.67%) | Buy |
| Median | 10.00 (1,115.07%) | |
| Low | 6.00 (BTIG, 629.04%) | Buy |
| Average | 13.67 (1,561.00%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 1.12 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| D. Boral Capital | 19 Feb 2026 | 25.00 (2,937.67%) | Buy | 1.15 |
| 09 Feb 2026 | 25.00 (2,937.67%) | Buy | 1.22 | |
| BTIG | 09 Feb 2026 | 6.00 (629.04%) | Buy | 1.22 |
| Benchmark | 21 Jan 2026 | 10.00 (1,115.07%) | Buy | 0.980 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 08 Jan 2026 | Announcement | Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications |
| 05 Jan 2026 | Announcement | Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |